Immunovant stock
IMVTNASDAQImmunovant, Inc., HealthcareISIN US45258J1025
45Score 45 out of 100, Weak
Price and trend
80 / 100
Price history
+62% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 18% below its 52-week high. Largest decline in 7 years: 94% (November 2020 to June 2022).
Chart figures for advanced users
- SMA 50$32.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$32.26
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.02
- The lowest closing price of the last twelve months.
- Resistance$44.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Immunovant, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $7.64B, is number 54 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 45 out of 100 (Weak): rank 466 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $722.27M, financial debt $0.Stability 74
Weaknesses
- DilutionShare count up 108% since 2021.Capital allocation 18
- Loss-makingLoss of $508.96M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$395.01M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 0%, operating 0%, net 0%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 5 Feb 2027in 85 days
- Last reported
- 9 Nov 2026EPS reported −$0.47 (expected −$0.74)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.940.0%
- Revenue
- $6.64M0.0%
- Earnings per share
- −$2.920.0%
- Revenue
- $42.94M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $12.95M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Girao TiagoSale
28 Oct 2026, Chief Financial Officer
- Shares
- 6,606
- Price
- $28.50
- Value
- $188,271
- Stout Jay SSale
21 Oct 2026, Chief Technology Officer
- Shares
- 2,595
- Price
- $28.94
- Value
- $75,099
- Stout Jay SSale
7 Oct 2026, Chief Technology Officer
- Shares
- 3,809
- Price
- $32.06
- Value
- $122,117
Show 23 more
- Van Tuyl ChristopherSale
7 Oct 2026, Chief Legal Officer
- Shares
- 1,327
- Price
- $32.06
- Value
- $42,544
- Gloria MelanieSale
7 Oct 2026, Chief Operating Officer
- Shares
- 2,241
- Price
- $32.06
- Value
- $71,846
- Venker EricSale
2 Oct 2026, Chief Executive Officer
- Shares
- 3,506
- Price
- $34.11
- Value
- $119,590
- Van Tuyl ChristopherSale
23 Sept 2026, Chief Legal Officer
- Shares
- 2,846
- Price
- $36.36
- Value
- $103,481
- Pande AtulSale
28 Aug 2026, Board
- Shares
- 1,500
- Price
- $43.27
- Value
- $64,905
- Gloria MelanieSale
20 Aug 2026, Chief Operating Officer
- Shares
- 3,056
- Price
- $44.16
- Value
- $134,953
- Pande AtulSale
24 Jul 2026, Board
- Shares
- 1,500
- Price
- $39.80
- Value
- $59,700
- Girao TiagoSale
23 Jul 2026, Chief Financial Officer
- Shares
- 6,798
- Price
- $38.69
- Value
- $263,015
- Stout Jay SSale
23 Jul 2026, Chief Technology Officer
- Shares
- 2,857
- Price
- $38.69
- Value
- $110,537
- Gloria MelanieSale
8 Jul 2026, Chief Operating Officer
- Shares
- 2,036
- Price
- $39.55
- Value
- $80,532
- Van Tuyl ChristopherSale
8 Jul 2026, Chief Legal Officer
- Shares
- 1,206
- Price
- $39.55
- Value
- $47,702
- Stout Jay SSale
8 Jul 2026, Chief Technology Officer
- Shares
- 3,487
- Price
- $39.55
- Value
- $137,925
- Venker EricSale
2 Jul 2026, Chief Executive Officer
- Shares
- 3,092
- Price
- $38.48
- Value
- $118,980
- Gloria MelanieSale
26 Jun 2026, Chief Operating Officer
- Shares
- 17,714
- Price
- $38.31
- Value
- $678,604
- Stout Jay SSale
26 Jun 2026, Chief Technology Officer
- Shares
- 40,000
- Price
- $38.31
- Value
- $1.53M
- Van Tuyl ChristopherSale
26 Jun 2026, Chief Legal Officer
- Shares
- 17,824
- Price
- $38.31
- Value
- $682,887
- Girao TiagoSale
26 Jun 2026, Chief Financial Officer
- Shares
- 10,000
- Price
- $38.46
- Value
- $384,600
- Pande AtulSale
26 Jun 2026, Board
- Shares
- 1,500
- Price
- $38.01
- Value
- $57,015
- Van Tuyl ChristopherSale
18 Jun 2026, Chief Legal Officer
- Shares
- 2,634
- Price
- $35.39
- Value
- $93,217
- Pande AtulSale
15 Jun 2026, Board
- Shares
- 1,500
- Price
- $34.02
- Value
- $51,030
- Fromkin Andrew J.Sale
28 May 2026, Board
- Shares
- 221,951
- Price
- $33.51
- Value
- $7.44M
- Gloria MelanieSale
20 May 2026, Chief Operating Officer
- Shares
- 3,115
- Price
- $32.45
- Value
- $101,072
- Pande AtulSale
20 May 2026, Board
- Shares
- 6,000
- Price
- $32.00
- Value
- $192,000
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Immunovant
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AbivaxABVX.PA $8.11B36
- Twist BioscienceTWST $8.07B45
- Axsome TherapeuticsAXSM $7.85B32
- Rhythm PharmaceuticalsRYTM $7.78B46
- Bachem HoldingBANB.SW $7.3B58
- ImmunityBioIBRX $7.1B38
- Caris Life SciencesCAI $7.02B58
- Arrowhead PharmaceuticalsARWR $6.97B32
ETFs that hold Immunovant
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.38% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.10% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.